Kongnakorn, T., Bharmal, M., Kearney, M., Phatak, H., Benedict, A., Bhanegaonkar, A., & Galsky, M. (2019). Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives. Clinicoecon Outcomes Res.
シカゴスタイル引用形Kongnakorn, Thitima, Murtuza Bharmal, Mairead Kearney, Hemant Phatak, Agnes Benedict, Abhijeet Bhanegaonkar, , Matthew Galsky. "Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives." Clinicoecon Outcomes Res 2019.
MLA引用形式Kongnakorn, Thitima, et al. "Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives." Clinicoecon Outcomes Res 2019.